NCT01961947View on ClinicalTrials.gov

Study of ASP7374, Cell-culture-derived Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
InfluenzaVaccine
Interventions
BIOLOGICAL

ASP7374

subcutaneous

BIOLOGICAL

approved egg-derived TIV

subcutaneous

Trial Locations (2)

Unknown

Kanto

Kyushu

All Listed Sponsors
lead

UMN Pharma Inc.

INDUSTRY

NCT01961947 - Study of ASP7374, Cell-culture-derived Influenza Vaccine | Biotech Hunter | Biotech Hunter